temozolomide has been researched along with Paraganglioma in 10 studies
Paraganglioma: A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion, such as the carotid body, or medulla of the adrenal gland (usually called a chromaffinoma or pheochromocytoma). It is more common in women than in men. (Stedman, 25th ed; from Segen, Dictionary of Modern Medicine, 1992)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cyclophosphamide-dacarbazine-vincristine regimen is recommended for the treatment of malignant pheochromocytoma and paraganglioma (MPP); however, dacarbazine is the only recognized active drug in neuroendocrine tumours." | 7.80 | SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. ( Al Ghuzlan, A; Amar, L; Baudin, E; Bertherat, J; Borget, I; Caramella, C; Chougnet, C; Déandreis, D; Deschamps, F; Dumont, F; Favier, J; Gimenez-Roqueplo, AP; Hadoux, J; Leboulleux, S; Letouzé, E; Libé, R; Loriot, C; Schlumberger, M; Scoazec, JY; Young, J, 2014) |
| "We report on the efficacy and safety of short-term administration of temozolomide, an inhibitor of nucleoside incorporation, in a 60-year-old woman with widespread hepatic metastases from a malignant paraganglioma." | 7.75 | Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report. ( Bravo, EL; Gill, I; Kalmadi, SR, 2009) |
| "Temozolomide (TMZ) has been shown to determine radiological and biochemical response in malignant PCC/PGLs." | 5.48 | Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma. ( Bertorelle, R; Ferrara, AM; Iacobone, M; Lombardi, G; Meringolo, D; Nardin, M; Opocher, G; Pambuku, A; Schiavi, F; Zagonel, V; Zovato, S, 2018) |
| "Ten percent of paragangliomas are malignant and one-third occurs in a genetic background." | 5.38 | A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine. ( Borson-Chazot, F; Giraud, S; Joly, MO; Lombard-Bohas, C; Nozières, C; Riou, JP; Scoazec, JY; Simon, C; Walter, T, 2012) |
| "The therapeutic options for metastatic pheochromocytomas/paragangliomas (mPPGLs) include chemotherapy with cyclophosphamide/vincristine/dacarbazine (CVD), temozolomide monotherapy, radionuclide therapies, and tyrosine kinase inhibitors such as sunitinib." | 4.31 | Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study. ( Auernhammer, CJ; Bechmann, N; Beuschlein, F; Bornstein, SR; Dischinger, U; Fischer, A; Fliedner, SMJ; Grossman, AB; Hantel, C; Kloos, S; Kroiss, M; Maurer, J; Mohr, H; Nölting, S; Pacak, K; Pamporaki, C; Pellegata, NS; Reincke, M; Remde, H; Reul, A; Robledo, M; Timmers, HJLM; Wang, K, 2023) |
| "Cyclophosphamide-dacarbazine-vincristine regimen is recommended for the treatment of malignant pheochromocytoma and paraganglioma (MPP); however, dacarbazine is the only recognized active drug in neuroendocrine tumours." | 3.80 | SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. ( Al Ghuzlan, A; Amar, L; Baudin, E; Bertherat, J; Borget, I; Caramella, C; Chougnet, C; Déandreis, D; Deschamps, F; Dumont, F; Favier, J; Gimenez-Roqueplo, AP; Hadoux, J; Leboulleux, S; Letouzé, E; Libé, R; Loriot, C; Schlumberger, M; Scoazec, JY; Young, J, 2014) |
| "We report on the efficacy and safety of short-term administration of temozolomide, an inhibitor of nucleoside incorporation, in a 60-year-old woman with widespread hepatic metastases from a malignant paraganglioma." | 3.75 | Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report. ( Bravo, EL; Gill, I; Kalmadi, SR, 2009) |
| "Temozolomide (TMZ) has been shown to determine radiological and biochemical response in malignant PCC/PGLs." | 1.48 | Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma. ( Bertorelle, R; Ferrara, AM; Iacobone, M; Lombardi, G; Meringolo, D; Nardin, M; Opocher, G; Pambuku, A; Schiavi, F; Zagonel, V; Zovato, S, 2018) |
| "Ten percent of paragangliomas are malignant and one-third occurs in a genetic background." | 1.38 | A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine. ( Borson-Chazot, F; Giraud, S; Joly, MO; Lombard-Bohas, C; Nozières, C; Riou, JP; Scoazec, JY; Simon, C; Walter, T, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 5 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Perez, K | 1 |
| Jacene, H | 1 |
| Hornick, JL | 1 |
| Ma, C | 1 |
| Vaz, N | 1 |
| Brais, LK | 1 |
| Alexander, H | 1 |
| Baddoo, W | 1 |
| Astone, K | 1 |
| Esplin, ED | 1 |
| Garcia, J | 1 |
| Halperin, DM | 1 |
| Kulke, MH | 1 |
| Chan, JA | 1 |
| Wang, K | 2 |
| Crona, J | 1 |
| Beuschlein, F | 2 |
| Grossman, AB | 2 |
| Pacak, K | 2 |
| Nölting, S | 2 |
| Singh, C | 1 |
| Bindra, RS | 1 |
| Glazer, PM | 1 |
| Vasquez, JC | 1 |
| Pashankar, F | 1 |
| Urquhart, C | 3 |
| Fleming, B | 3 |
| Harper, I | 3 |
| Aloj, L | 3 |
| Armstrong, R | 3 |
| Hook, L | 3 |
| Long, AM | 3 |
| Jackson, C | 3 |
| Gallagher, FA | 3 |
| McLean, MA | 3 |
| Tarpey, P | 3 |
| Kosmoliaptsis, V | 3 |
| Nicholson, J | 3 |
| Hendriks, AEJ | 3 |
| Casey, RT | 3 |
| Fischer, A | 1 |
| Kloos, S | 1 |
| Remde, H | 1 |
| Dischinger, U | 1 |
| Pamporaki, C | 1 |
| Timmers, HJLM | 1 |
| Robledo, M | 1 |
| Fliedner, SMJ | 1 |
| Maurer, J | 1 |
| Reul, A | 1 |
| Bechmann, N | 1 |
| Hantel, C | 1 |
| Mohr, H | 1 |
| Pellegata, NS | 1 |
| Bornstein, SR | 1 |
| Kroiss, M | 1 |
| Auernhammer, CJ | 1 |
| Reincke, M | 1 |
| Ferrara, AM | 1 |
| Lombardi, G | 1 |
| Pambuku, A | 1 |
| Meringolo, D | 1 |
| Bertorelle, R | 1 |
| Nardin, M | 1 |
| Schiavi, F | 1 |
| Iacobone, M | 1 |
| Opocher, G | 1 |
| Zagonel, V | 1 |
| Zovato, S | 1 |
| Hadoux, J | 1 |
| Favier, J | 1 |
| Scoazec, JY | 2 |
| Leboulleux, S | 1 |
| Al Ghuzlan, A | 1 |
| Caramella, C | 1 |
| Déandreis, D | 1 |
| Borget, I | 1 |
| Loriot, C | 1 |
| Chougnet, C | 1 |
| Letouzé, E | 1 |
| Young, J | 1 |
| Amar, L | 1 |
| Bertherat, J | 1 |
| Libé, R | 1 |
| Dumont, F | 1 |
| Deschamps, F | 1 |
| Schlumberger, M | 1 |
| Gimenez-Roqueplo, AP | 1 |
| Baudin, E | 1 |
| Sait, S | 1 |
| Kobos, R | 1 |
| LaQuaglia, MP | 1 |
| Pandit-Taskar, N | 1 |
| Modak, S | 1 |
| Bravo, EL | 1 |
| Kalmadi, SR | 1 |
| Gill, I | 1 |
| Nozières, C | 1 |
| Walter, T | 1 |
| Joly, MO | 1 |
| Giraud, S | 1 |
| Borson-Chazot, F | 1 |
| Simon, C | 1 |
| Riou, JP | 1 |
| Lombard-Bohas, C | 1 |
2 reviews available for temozolomide and Paraganglioma
| Article | Year |
|---|---|
Targeted Therapies in Pheochromocytoma and Paraganglioma.
Topics: Adrenal Gland Neoplasms; Humans; Paraganglioma; Pheochromocytoma; Randomized Controlled Trials as To | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review.
Topics: Adrenal Gland Neoplasms; Adult; Brain Neoplasms; Child; Female; Humans; Neoplasms, Second Primary; P | 2022 |
8 other studies available for temozolomide and Paraganglioma
| Article | Year |
|---|---|
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
Topics: Adrenal Gland Neoplasms; Humans; Mutation; Paraganglioma; Pheochromocytoma; Retrospective Studies; S | 2022 |
Metastatic and multiply relapsed SDH-deficient GIST and paraganglioma displays clinical response to combined poly ADP-ribose polymerase inhibition and temozolomide.
Topics: Adenosine Diphosphate Ribose; DNA Repair; Gastrointestinal Stromal Tumors; Humans; Paraganglioma; Po | 2023 |
Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study.
Topics: Adrenal Gland Neoplasms; Brain Neoplasms; Cardiovascular Diseases; Cohort Studies; Humans; Iodine Ra | 2023 |
Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Leucine Zipper Tr | 2018 |
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarke | 2014 |
Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cytarabine; Dacarbazi | 2017 |
Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Middle Aged | 2009 |
A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Dacarbazine; | 2012 |